Concepedia

Author

Chikashi Yoshida

National Hospital Organization Mito Medical Center

Also Known As

C Yoshida, C. Yoshida, Cassidy Yoshida, Chikashi YOSHIDA, Chikashi Yoshida, Yoshida C.

89

Publications

1.1K

Citations

19

H-Index

45

Concepts

All Affiliations

National Hospital Organization Mito Medical CenterOme Municipal General HospitalNippon Medical SchoolTokyo Metropolitan Komagome HospitalTokai Central Hospital
CY

About

Chikashi Yoshida is an author at National Hospital Organization Mito Medical Center specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

382

2

Health Sciences

6

6

204

3

Cell Biology

4

4

142

4

Natural Sciences

2

2

44

5

Biology

1

1

16

Chikashi Yoshida

×

27

Publications

895

Citations

18

H-Index

YearCitations

A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling

Yoshiaki Abe, Mamiko Sakata‐Yanagimoto, Manabu Fujisawa,

Nature Cell Biology

2022

97

Long range interaction of cis‐DNA elements mediated by architectural transcription factor Bach1

Chikashi Yoshida, Fuyuki Tokumasu, Ken I. Hohmura,

Genes to Cells

1999

94

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation

Takashi Kumagai, Chiaki Nakaseko, Kaichi Nishiwaki,

Cancer Science

2017

64

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai,

The Lancet Haematology

2021

60

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1

Chikashi Yoshida, Fumiko Yoshida, D Sears,

Blood

2006

54

Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of <scp>K</scp>anto CML study group

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida,

American Journal of Hematology

2014

47

Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study

Yuho Najima, Chikashi Yoshida, Noriyoshi Iriyama,

Leukemia Research

2018

36

Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

Shin Fujisawa, Yasunori Ueda, Kensuke Usuki,

International Journal of Clinical Oncology

2018

36

Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study

Noriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida,

American Journal of Hematology

2015

35

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan

Chikashi Yoshida, Linda Fletcher, Kazuteru Ohashi,

International Journal of Clinical Oncology

2011

32

Page 1